{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:00:55Z","timestamp":1793419255074,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Novavax, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-026-26592-1","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T02:43:04Z","timestamp":1770864184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world impact of NVX-CoV2373 COVID-19 vaccine in immunocompromised individuals in South Korea"],"prefix":"10.1186","volume":"26","author":[{"given":"Eunseon","family":"Gwak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ah","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdenetuya","family":"Bolormaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela H.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muruga","family":"Vadivale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Rousculp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young June","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"26592_CR1","unstructured":"World Health Organization. WHO chief declares end to COVID-19 as a global health emergency. 2023 Updated May 5. 2023. Available from: https:\/\/news.un.org\/en\/story\/2023\/05\/1136367. Accessed 26 Mar 2025."},{"key":"26592_CR2","unstructured":"World Health Organization. Statement on the antigen composition of COVID-19 vaccines, Updated. May 18, 2023. Available from: https:\/\/www.who.int\/news\/item\/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines. Accessed 15 Aug 2024."},{"issue":"3","key":"26592_CR3","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Consortium C-GU, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023;21(3):162\u201377.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"26592_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s12325-023-02754-0","volume":"41","author":"A Ketkar","year":"2024","unstructured":"Ketkar A, Willey V, Glasser L, Dobie C, Wenziger C, Teng CC, et al. Assessing the burden and cost of COVID-19 across variants in commercially insured immunocompromised populations in the united states: updated results and trends from the ongoing EPOCH-US study. Adv Ther. 2024;41(3):1075\u2013102.","journal-title":"Adv Ther"},{"key":"26592_CR5","unstructured":"British Society for Immunology, Immunodeficiency. November. Updated 2017. Available from: https:\/\/www.immunology.org\/policy-and-public-affairs\/briefings-and-position-statements\/immunodeficiency. Accessed 15 Dec 2024."},{"key":"26592_CR6","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.eclinm.2023.101965","volume":"59","author":"S Shoham","year":"2023","unstructured":"Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, Hotez P, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine. 2023;59:101965.","journal-title":"EClinicalMedicine"},{"key":"26592_CR7","first-page":"100461","volume":"20","author":"T Bahremand","year":"2023","unstructured":"Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg Health Am. 2023;20:100461.","journal-title":"Lancet Reg Health Am"},{"key":"26592_CR8","unstructured":"2024 Updated Korean Disease Control and Prevention Agency. COVID-19 Vaccination, July. 30, 2024. Available from: https:\/\/dportal.kdca.go.kr\/pot\/www\/CVID19\/PRVNTN\/VCNTN.jsp?seq=TAB2_9. Accessed 16 Dec 2024."},{"issue":"5","key":"26592_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"issue":"5","key":"26592_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40520-023-02380-4","volume":"35","author":"K Bukan","year":"2023","unstructured":"Bukan K, Pearce-Slade T, Eiberg M, Tinelli M, Yahav D, Tuells J, et al. Exclusion of older adults and immunocompromised individuals in influenza, Pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic. Aging Clin Exp Res. 2023;35(5):917\u201323.","journal-title":"Aging Clin Exp Res"},{"issue":"6","key":"26592_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2116185","volume":"386","author":"LM Dunkle","year":"2022","unstructured":"Dunkle LM, Kotloff KL, Gay CL, Anez G, Adelglass JM, Barrat Hernandez AQ, et al. Efficacy and safety of NVX-CoV2373 in adults in the united States and Mexico. N Engl J Med. 2022;386(6):531\u201343.","journal-title":"N Engl J Med"},{"issue":"27","key":"26592_CR12","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"key":"26592_CR13","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"A Lee","year":"2022","unstructured":"Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632.","journal-title":"BMJ"},{"issue":"12","key":"26592_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.15585\/mmwr.mm7312a5","volume":"73","author":"R Link-Gelles","year":"2024","unstructured":"Link-Gelles R, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, et al. Interim effectiveness of updated 2023\u20132024 (Monovalent XBB.1.5) COVID-19 vaccines against COVID-19-Associated hospitalization among adults aged >\/=18 years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024;73(12):271\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"26592_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14760584.2022.2035222","volume":"21","author":"M Di Fusco","year":"2022","unstructured":"Di Fusco M, Lin J, Vaghela S, Lingohr-Smith M, Nguyen JL, Scassellati Sforzolini T, et al. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines. 2022;21(4):435\u201351.","journal-title":"Expert Rev Vaccines"},{"key":"26592_CR16","unstructured":"Ministry of Food and Drug Safety. COVID-19 Vaccine Regulatory Website. 2024 Updated September 11, 2024. Available from: https:\/\/www.mfds.go.kr\/vaccine_covid19.jsp. Accessed 12 Sept 2024."},{"issue":"13","key":"26592_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172\u201383.","journal-title":"N Engl J Med"},{"key":"26592_CR18","doi-asserted-by":"publisher","first-page":"126777","DOI":"10.1016\/j.vaccine.2025.126777","volume":"49","author":"MH Gschwend","year":"2025","unstructured":"Gschwend MH, Marchese AM, Poelaert D, Warren B, Rousculp MD, Caldera F. Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review. Vaccine. 2025;49:126777.","journal-title":"Vaccine"},{"key":"26592_CR19","unstructured":"Nextstrain.org. Genomic epidemiology of SARS-CoV-2 with subsampling focused on Asia Updated December 15. 2024. Available from: https:\/\/nextstrain.org\/ncov\/gisaid\/asia\/all-time?dmax=2023-03-31&dmin=2022-01-18. Accessed 16 Dec 2024."},{"issue":"3","key":"26592_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cmet.2017.02.006","volume":"25","author":"N Zmora","year":"2017","unstructured":"Zmora N, Bashiardes S, Levy M, Elinav E. The role of the immune system in metabolic health and disease. Cell Metabol. 2017;25(3):506\u201321.","journal-title":"Cell Metabol"},{"issue":"13","key":"26592_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.2020.1943","volume":"323","author":"B Lebwohl","year":"2020","unstructured":"Lebwohl B, Green PHR, Soderling J, Roelstraete B, Ludvigsson JF. Association between Celiac disease and mortality risk in a Swedish population. JAMA. 2020;323(13):1277\u201385.","journal-title":"JAMA"},{"key":"26592_CR22","doi-asserted-by":"crossref","unstructured":"Gwak E, Choe S-A, Kim K, Bolormaa E, Fix J, Vadivale M et al. Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea. MedRxiv. 2024:2024.11.26.24317925.","DOI":"10.1101\/2024.11.26.24317925"},{"key":"26592_CR23","unstructured":"World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020 Updated February 16\u201324, 2020. Available from: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed 22 Jul 2025."},{"issue":"7","key":"26592_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1473-3099(20)30195-X","volume":"20","author":"D Baud","year":"2020","unstructured":"Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20(7):773.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"26592_CR25","doi-asserted-by":"publisher","first-page":"e1259","DOI":"10.1002\/iid3.1259","volume":"12","author":"J Bytyci","year":"2024","unstructured":"Bytyci J, Ying Y, Lee LYW. Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review. Immun Inflamm Dis. 2024;12(4):e1259.","journal-title":"Immun Inflamm Dis"},{"issue":"10","key":"26592_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","volume":"55","author":"S DeWolf","year":"2022","unstructured":"DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022;55(10):1779\u201398.","journal-title":"Immunity"},{"issue":"3","key":"26592_CR27","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.jinf.2025.106432","volume":"90","author":"JK Quint","year":"2025","unstructured":"Quint JK, Dube S, Carty L, Yokota R, Bell S, Turtle L, et al. Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study. J Infect. 2025;90(3):106432.","journal-title":"J Infect"},{"key":"26592_CR28","unstructured":"National Institute of Arthritis and Musculoskeletal and Skin Diseases. Arthritis and Rheumatic Diseases. 2023 Updated September 2023. Available from: https:\/\/www.niams.nih.gov\/health-topics\/arthritis-and-rheumatic-diseases. Accessed 30 Jan 2025."},{"issue":"1","key":"26592_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41378-023-00616-x","volume":"9","author":"S Abizanda-Campo","year":"2023","unstructured":"Abizanda-Campo S, Virumbrales-Mu\u00f1oz M, Humayun M, Marmol I, Beebe DJ, Ochoa I, et al. Microphysiological systems for solid tumor immunotherapy: opportunities and challenges. Microsystems Nanoengineering. 2023;9(1):154.","journal-title":"Microsystems Nanoengineering"},{"key":"26592_CR30","doi-asserted-by":"crossref","unstructured":"Balogh L, Ol\u00e1h K, S\u00e1nta S, Majerhoffer N, N\u00e9meth T. Novel and potential future therapeutic options in systemic autoimmune diseases. Front Immunol. 2024;15:1249500.","DOI":"10.3389\/fimmu.2024.1249500"},{"issue":"2","key":"26592_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/09540121.2015.1074653","volume":"28","author":"KG Buell","year":"2016","unstructured":"Buell KG, Chung C, Chaudhry Z, Puri A, Nawab K, Ravindran RP. Lifelong antiretroviral therapy or HIV cure: the benefits for the individual patient. AIDS Care. 2016;28(2):242\u20136.","journal-title":"AIDS Care"},{"issue":"12","key":"26592_CR32","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","volume":"104","author":"BL Stewart","year":"2004","unstructured":"Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501\u20136.","journal-title":"Blood"},{"key":"26592_CR33","doi-asserted-by":"crossref","unstructured":"Sochacka-\u0106wik\u0142a A, M\u0105czy\u0144ski M, Regiec A. FDA-Approved drugs for hematological Malignancies-The last decade review. Cancers (Basel). 2021;14(1):87.","DOI":"10.3390\/cancers14010087"},{"issue":"6","key":"26592_CR34","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2665-9913(24)00065-1","volume":"6","author":"CS Goodyear","year":"2024","unstructured":"Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, de Silva TI, et al. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Rheumatol. 2024;6(6):e339\u201351.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"26592_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood.2021012412","volume":"141","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Chen YB. How I treat with maintenance therapy after allogeneic HCT. Blood. 2023;141(1):39\u201348.","journal-title":"Blood"},{"issue":"8","key":"26592_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/phar.2716","volume":"42","author":"J Nelson","year":"2022","unstructured":"Nelson J, Alvey N, Bowman L, Schulte J, Segovia MC, McDermott J, et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American college of clinical Pharmacy, American society of transplantation, and the international society for heart and lung transplantation. Pharmacotherapy. 2022;42(8):599\u2013633.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"26592_CR37","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1093\/ndt\/gfad010","volume":"38","author":"A Nowak","year":"2023","unstructured":"Nowak A, Hemmingsson P, Evans M, Wijkstrom J. Serological response to Nuvaxovid (NVX-CoV2373) vaccine given as a fifth dose in non- and low-responder kidney transplant recipients. Nephrol Dial Transpl. 2023;38(6):1564\u20136.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"26592_CR38","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/S2665-9913(23)00298-9","volume":"6","author":"A Abhishek","year":"2024","unstructured":"Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Francis A, et al. Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. Lancet Rheumatol. 2024;6(2):e92\u2013104.","journal-title":"Lancet Rheumatol"},{"issue":"20","key":"26592_CR39","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1016\/j.vaccine.2023.03.065","volume":"41","author":"M Frodlund","year":"2023","unstructured":"Frodlund M, Nived P, Chatzidionysiou A, S\u00f6dergren A, Klingberg E, Bengtsson A, et al. The impact of Immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA). Vaccine. 2023;41(20):3247\u201357.","journal-title":"Vaccine"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-26592-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26592-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26592-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:34:12Z","timestamp":1773830052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-26592-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["26592"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-26592-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in accordance with the REporting of studies Conducted using Observational Routinely-collected Data (RECORD) guidelines and relevant local regulations. Patient consent forms and formal review by an institutional review board were not required for this type of research (Korea University Institutional Review Board exemption No. 2024AN0084).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication from all participants whose data are included in this manuscript is not required for this type of research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EG, SAC, KK, EB, and YJC are study investigators and do not have any conflicts of interest to report. JF, MHG, and MDR are employees of Novavax, Inc. and may own stock. MV was a salaried employee of Novavax, Inc. and may own stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"913"}}